Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.

Toronto Public Health says it observed “many deviations from best practices” during an inspection at the gynecologist's ...

A yearly injection such as Lenacapavir could help overcome barriers to PrEP accessibility by increasing its uptake and making ...

HIV self-testing remains underutilized among not only the general public, but especially people who use drugs.

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Philadelphia Center hosts event with free food and drag performances to raise awareness on HIV Criminalization and its ...

The letter said patients who received endometrial biopsies, IUD insertions or had cervical growths removed at the clinic ...

Pre-exposure prophylaxis (PrEP) is the advent of antiretroviral treatment use for people at increased risk of acquiring HIV-1 ...

Researchers from the HIV Prevention Trials Network (HPTN) have presented results from the HPTN 094 ("INTEGRA") study at the ...

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...